Skip to main content
SpringerLink
Log in

Update in testicular cancer

  • Conference paper
Progress in Anti-Cancer Chemotherapy

Part of the book series: Progress in Anti-Cancer Chemotherapy ((ANTI-CANCER,volume 3))

  • 60 Accesses

Abstract

Germ cell tumors are relatively uncommon, accounting for only 1% of male malignancies in the United States. The highest worldwide incidence is in Scandinavian countries; by contrast, testicular cancer is rare in African Americans. The primary age group is 15–l35 for nonseminomatous tumors and a decade older for seminoma. Thus, the potential for loss of productive years of life has always made testis cancer important both medically and economically.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Einhorn LH (1981) Testicular cancer: A model for a curable neoplasm. Cancer Research 41:3275–3280

    PubMed  CAS  Google Scholar 

  2. Einhorn LH (1990) Treatment of testicular cancer: A new and improved model. J Clin Oncol 8:1777–1781

    PubMed  CAS  Google Scholar 

  3. Bosl GJ, Motzer RJ (1997) Testicular germ cell cancer. NEJM 337:242–253

    Article  PubMed  CAS  Google Scholar 

  4. Li MC, Whitmore WF, Golbey R et al (1960) Effects of combined drug therapy on metastatic cancer of the testis. JAMA 174:145–153

    Article  Google Scholar 

  5. Samuels ML, Lanzotti VJ, Holoye PY et al (1976) Combination chemotherapy in germinal cell tumors. Cancer Treat Rev 3:185–204

    Article  PubMed  CAS  Google Scholar 

  6. Rosenberg B, VanCamp L, Krigas T (1965) Inhibition of cell division in e. coli by electrolysis products from a platinum electrode. Nature 205:678–699

    Article  Google Scholar 

  7. Higby DJ, Wallace HJ, Albert DJ et al (1974) Diamminedichloroplatinum: A phase I study showing responses in testicular and other tumors. Cancer 33:1219–1225

    Article  PubMed  CAS  Google Scholar 

  8. Einhorn LH, Donohue JP (1977) Combination chemotherapy with cis-diam- minedichloroplatinum, vinblastine, and bleomycin in disseminated testicular cancer. Ann Int Med 87:293–298

    PubMed  CAS  Google Scholar 

  9. Einhorn LH, Williams SD, Troner M, Greco FA, Birch R (1981) The rise of maintenance therapy in disseminated testicular cancer: A Southeastern Cancer Study Group Protocol. NEJM 305:717–731

    Article  Google Scholar 

  10. Fitzharris BM, Kaye SB, Saverymuttu S et al (1980) VP-16 as single agent in advanced testicular tumors. Eur J Cancer 16:1193–1197

    PubMed  CAS  Google Scholar 

  11. Schabel FM Jr, Trader MW, Laster WR Jr et al (1979) Cisplatin: combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63:1459–1473

    PubMed  CAS  Google Scholar 

  12. Williams SD, Birch R, Irwin L, Greco A, Loehrer PJ, Einhorn LH (1987) Disseminated germ cell tumors: chemotherapy with cisplatin plus bleomycin plus either vinblastine or etoposide. NEJM 316:1435–1440

    Article  PubMed  CAS  Google Scholar 

  13. Birch R, Williams SD, Cone A, Einhorn LH et al (1986) Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4:400–407

    PubMed  CAS  Google Scholar 

  14. Bosl GJ, Geller NL, Cirrincione C et al (1983) Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43:3403–3407

    PubMed  CAS  Google Scholar 

  15. Einhorn LH, Williams, SD, Loehrer PJ et al (1989) Evaluation of optimal duration of chemotherapy in favorable prognosis disseminated germ cell tumors: An SECSG Protocol. J Clin Oncol 7:387–391

    PubMed  CAS  Google Scholar 

  16. Saxman S, Finch D, Gonin R, Einhorn LH (1998) Long-term follow-up of a phase III study of 3 versus 4 cycles of bleomycin, etoposide, and cisplatin in favorable prognosis germ cell tumors: The Indiana University experience. J Clin Oncol 16:702–706

    PubMed  CAS  Google Scholar 

  17. Loehrer PJ, Einhorn LH, Elson P et al (1995) The importance of bleomycin in favorable prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group Trial. J Clin Oncol 13:470–476

    PubMed  Google Scholar 

  18. de Wit R, Stoter G, Kaye SB et al (1997) Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15:1837–1843

    PubMed  Google Scholar 

  19. Bosl GJ, Geller NL, Bajorin D, Leitner SP, Yagoda A et al (1988) A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6:1231–1238

    PubMed  CAS  Google Scholar 

  20. Bajorin DE, Geller NL, Weisen SE, Bosl GJ (1991) Two-drug therapy in patients with metastatic germ cell tumors. Cancer 67:28–32

    Article  PubMed  CAS  Google Scholar 

  21. Xiao H, Mazumdar M, Bajorin DE et al (1997) Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. Proc Amer Soc Clin Oncol 16:321

    CAS  Google Scholar 

  22. Horwich A, Sleijfer DT, Fossa SD, Kay SB, Oliver RTD et al (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A Multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15:1844–1852

    PubMed  CAS  Google Scholar 

  23. Bajorin D, Sarosdy ME, Pfister DG et al (1993) Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors. J Clin Oncol 11:598–608

    PubMed  CAS  Google Scholar 

  24. International Germ Cell Collaborative Group (1997) International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594–603

    Google Scholar 

  25. Nichols CR, Williams SD, Einhorn LH et al (1991) Randomized study of cisplatin dose intensity in advanced germ cell tumors: An SECSG and SWOG protocol. J Clin Oncol 9:1163–1172

    PubMed  CAS  Google Scholar 

  26. Nichols CR, Loehrer PJ, Einhorn LH et al (1997) Phase III study of BEP versus VIP in advanced stage germ cell tumors: An intergroup trial. J Clin Oncol 16:1287–1293

    Google Scholar 

  27. Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH (1992) Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16:2500–2504

    Google Scholar 

  28. Broun ER, Nichols CR, Einhorn LH et al (1992) Long-term follow-up of salvage chemotherapy in relapsed and refractory germ cell tumors using high dose carboplatin and etoposide with autologous bone marrow support. Annals Intern Med 117:124–128

    CAS  Google Scholar 

  29. Bhatia S, Cometta K, Broun R, Nichols C, Abnour R, Einhorn LH (1998) High dose chemotherapy with peripheral stem cell or autologous transplant as initial salvage chemotherapy for testicular cancer. Proc Amer Soc Clin Oncol 17:321 (abstr)

    Google Scholar 

  30. Miller KD, Loehrer PJ, Gonin R, Einhorn LH (1997) Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol 15:1427–1431

    PubMed  CAS  Google Scholar 

  31. Saxman SB, Nichols CR, Einhorn LH et al (1996) The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers. J Urol 155:587–589

    Article  PubMed  CAS  Google Scholar 

  32. Davis BE, Herr HW, Fair WR, Bosl GJ (1994) The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J Urol 152:111–114

    PubMed  CAS  Google Scholar 

  33. Sheinfield J, Puc HS et al (1997) Surgery for a post-chemotherapy residual mass in seminoma. J Urol 157:860–862

    Article  Google Scholar 

  34. Schultz SM, Einhorn, LH, Conces D et al (1989) Management of post-chemotherapy residual mass in patients with advanced seminoma: Indiana University Experience. J Clin Oncol 7:1497–1503

    PubMed  CAS  Google Scholar 

  35. Horwich A, Paluchowska B, Norman A et al (1997) Residual mass following chemotherapy of seminoma. Ann Oncol 8:37–40

    Article  PubMed  CAS  Google Scholar 

  36. Toner GC, Panciek DM, Heelan RT et al (1990) Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 8:1683–1694

    PubMed  CAS  Google Scholar 

  37. Debono DJ, Heilman DK, Einhorn LH, Donohue JP (1997) Decision analysis for avoiding post-chemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 15:1455–1464

    PubMed  CAS  Google Scholar 

  38. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH (1995) Late relapse of testicular cancer. J Clin Oncol 13: 1170–1176

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. L. H. Einhorn
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. MD Anderson Cencer Center, Cepartment of Breast Medical Oncology, University of Texas, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA

    Gabriel N. Hortobagyi

  2. Pitié-Salpétrière Hospital, SOMPS, 47, bd de l’Hôpital, 75651, Paris Cedex 13, France

    David Khayat

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag France

About this paper

Cite this paper

Einhorn, L.H. (1999). Update in testicular cancer. In: Hortobagyi, G.N., Khayat, D. (eds) Progress in Anti-Cancer Chemotherapy. Progress in Anti-Cancer Chemotherapy, vol 3. Springer, Paris. https://doi.org/10.1007/978-2-8178-0918-2_9

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0918-2_9

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-59666-7

  • Online ISBN: 978-2-8178-0918-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation